The relative posterior probabilities of treatment success with regard to
the primary outcome for each drug are shown. The percentage of patients with
treatment success was 47% (95% credible interval, 39 to 55) in the levetiracetam
group, 45% (95% credible interval, 36 to 54) in the fosphenytoin group, and 46%
(95% credible interval, 38 to 55) in the valproate group.